Iridex Q3 revenue slides on lower international retina sales; cuts FY26 revenue guidance
IRIX•
IRIX•Iridex said third-quarter revenue fell 19% year over year to $10.2 million and cut its fiscal 2026 revenue outlook to $46 million-$48 million from $51 million-$53 million.
Iridex's third-quarter revenue fell 19% year over year to $10.2 million, below the $12.65 million consensus estimate. Net loss narrowed to $1.4 million from $1.57 million a year earlier. The company cut its fiscal 2026 revenue guidance to $46 million-$48 million from $51 million-$53 million and expects adjusted operating expenses of $19 million-$19.5 million.
Lower international retina sales and probe orders drove the revenue decline, as demand weakened in Europe and Asia and distributors worked through probe inventory and regulatory challenges. Growth in the U.S. glaucoma business partially offset the decline. Gross margin rose because of the absence of a prior-year inventory write-off, favorable geographic mix and sustained pricing discipline; Iridex expects margin expansion through 2027 as it transitions to contract manufacturers.